May 21, 2026
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in OncologyApril 28, 2026
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celFebruary 23, 2026
Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-celFebruary 06, 2026
FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma